Literature DB >> 3161996

[3H]205-501, a non-catechol dopaminergic agonist, labels selectively and with high affinity dopamine D2 receptors.

A Closse, W Frick, R Markstein, R Maurer, R Nordmann.   

Abstract

[3H]205-501, a noncatechol dopaminergic agonist, is presented as a ligand with high affinity (KD approximately 1 nM) and high selectivity for dopamine receptors. pKi values of dopaminergic agonists derived from competition isotherms in the [3H]205-501 binding assay correlate very well with their potency in the acetylcholine release assay, which is controlled by dopamine D2 receptors. There is however no correlation with their potency stimulating adenylate cyclase, a process controlled by dopamine D1 receptors. Thus [3H]205-501 is the first agonist ligand selective for dopamine D2 receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3161996     DOI: 10.1007/bf01252239

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  29 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

3.  Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

Authors:  J W Kebabian; G L Petzold; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1972-08       Impact factor: 11.205

Review 4.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

5.  In vitro acetylcholine release from rat caudate nucleus as a new model for testing drugs with dopamine-receptor activity.

Authors:  J C Stoof; R E Thieme; M C Vrijmoed-de Vries; A H Mulder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-11       Impact factor: 3.000

6.  3H-Spiroperidol labels dopamine receptors in pituitary and brain.

Authors:  I Creese; R Schneider; S H Snyder
Journal:  Eur J Pharmacol       Date:  1977-12-15       Impact factor: 4.432

Review 7.  Dopaminergic 3H-agonist receptors in rat brain. New evidence on localization and pharmacology.

Authors:  N G Bacopoulos
Journal:  Life Sci       Date:  1984-01-23       Impact factor: 5.037

8.  Two novel prolactin release-inhibiting 8 alpha-amino-ergolines.

Authors:  E Flückiger; U Briner; H R Bürki; P Marbach; H R Wagner; W Doepfner
Journal:  Experientia       Date:  1979-12-15

9.  Cation regulation differentiates specific binding of [3H]sulpiride and [3H]spiperone to rat striatal preparations.

Authors:  A E Theodorou; M D Hall; P Jenner; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1980-06       Impact factor: 3.765

10.  Three classes of dopamine receptor (D-2, D-3, D-4) identified by binding studies with 3H-apomorphine and 3H-domperidone.

Authors:  P Sokoloff; M P Martres; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980       Impact factor: 3.000

View more
  4 in total

1.  SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors.

Authors:  R Markstein; P Gull; C Rüdeberg; S Urwyler; A L Jaton; H O Kalkman; A K Dixon; D Hoyer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Pharmacodynamic profile of CQP 201-403, a novel 8 alpha-amino-ergoline.

Authors:  E Flückiger; U Briner; B Clark; A Closse; A Enz; P Gull; A Hofmann; R Markstein; L Tolcsvai; H R Wagner
Journal:  Experientia       Date:  1988-05-15

3.  5-HT1A receptor agonists prevent in rats the yawning and penile erections induced by direct dopamine agonists.

Authors:  P Simon; B Guardiola; J Bizot-Espiard; P Schiavi; J Costentin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

4.  Multifocal sites of action involved in dopaminergic-cholinergic neuronal interactions in yawning.

Authors:  I Ushijima; Y Mizuki; M Yamada
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.